Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer

Figure 7

Survival curves were calculated using Kaplan-Meier assays for the exploration of the possible influence of PTK6 expression on disease-specific survival of BC patients. (a) All BC patients. (b) Patients with negative PR status. (c) Patients with positive PR status. (d) Patients with negative HER2 status. (e) Patients with positive HER2 status. (f) Patients with negative ER status. (g) Patients with positive ER status.

(a)

(b)

(c)

(d)

(e)

(f)

(g)